Searched for
BIOSIMILAR ADALIMUMAB
Biocon Biologics gets global rights for biosimilar AdalimumabBiocon Biologics has gained complete global rights for Hulio, a biosimilar Adalimumab. This move grants Biocon Biologics full control over ...- Acceleration of biosimilar business, debt reduction to be key priorties in FY25: Biocon ChiefKiran Mazumdar-Shaw of Biocon aims to consolidate, accelerate biosimilar business, and reduce debt after Viatris acquisition in FY25. Mazum...
- Biocon Biologics focusing on market share gains of biosimilars in key marketsBiocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Eur...
- Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in JapanAdalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylos...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- Biocon Biologics launches biosimilar adalimumab in USAdalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...
- Biocon Biologics may raise additional equity of $300 million in FY24 to pare debtBiocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...
- Alkem subsidiary Enzene launches adalimumab biosimilar in IndiaEnzene or its parent Alkem which is commercialising the drug didn't announce the price, but said it would be competitively priced.
- Cipla Gulf expands partnership with Alvotech for commercialisation of four drugs in Australia, New ZealandCipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...
- Glenmark launches biosimilar Adalimumab in IndiaGlenmark did not give any financial detail for the drug, but globally Adalimumab is estimated to be a $16 billion drug in 2016, making it t...
- Hetero launches HumiraTM biosimilar in IndiaThe product will be marketed by Hetero Healthcare under the brand name ‘MaburaTM’ in India, the company said.
- Reliance Life gains global rights for copies of InfliximabFor Infliximab, Reliance Life Sciences had completed process development, manufacturing, clinical trials in India and obtained marketing ap...
- Biocon rallies nearly 7% as Morgan Stanley upgrades stock to ‘overweight’Key risks for Biocon going ahead include delay in launch of four key biosimilars in US or EU due to regulatory challenges, as well as highe...
- Biocon Q3 net up 13% at Rs 103 croreThe company had posted net profit of Rs 90.9 crore for the October-December period of the 2014-15 fiscal, Biocon said in a statement.
- Torrent Pharma launches Adalimumab biosimilar in IndiaThe company's product will be available as pre-filled syringe of 40 mg, Torrent Pharmaceuticals said in a statement.
- Biocon targets emerging, developed markets with biosimilars"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...
- Biocon, Mylan drug discovery programme to treat cancer, arthritis makes progressBiocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...
- Zydus Cadila launches biosimilar of AbbVie's Humira in IndiaZydus Cadila today launched biosimilar of Adalimumab, used for treatment of auto immune disorders, at a price much lower than the innovator...
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.
Load More
